Introduction
============

Patients undergoing nephrectomy have a high incidence of postoperative pain despite the use of modern laparoscopic surgical techniques. In the postoperative period, these patients are often treated with patient-controlled opioids, epidural analgesia, or both. While effective, both of these treatment modalities carry risk, ie, opioids have a side effect profile including pruritus, nausea, and vomiting, and increase the risk of oversedation and apnea in patients at risk (eg, those with sleep apnea). Epidurals have been associated with hypotension, post dural puncture headaches, changes in management of anticoagulation, as well as rare but serious infections, bleeding, and nerve injury. Transversus abdominis plane (TAP) blocks have been described as a way of providing analgesia to the anterior abdominal wall with minimal risk.[@b1-lra-7-011] These blocks avoid the potential hazards associated with opioids and neuraxial blockade. Use of ultrasound to correctly identify structures during administration of these blocks should theoretically further lessen the risk of complications.

To date, only a handful of prospective randomized studies have been performed examining the clinical utility of TAP blocks related to kidney transplant. The first three studies[@b2-lra-7-011]--[@b4-lra-7-011] showed improved pain scores in patients receiving the TAP block, while Frier et al[@b5-lra-7-011] showed no benefit. Additionally, Mukhtar and Khattak showed a decrease in nausea in the TAP group.[@b2-lra-7-011] The aim of this prospective, randomized, double-blind, placebo-controlled study was to evaluate the efficacy of TAP blocks in providing analgesia for patients undergoing laparoscopic hand-assisted nephrectomy for either tumor resection or kidney donation. Our hypothesis was that TAP block would result in a significant reduction in both opioid consumption (primary endpoint) and pain scores (secondary endpoint) in the 24-hour period following surgery.

Materials and methods
=====================

The study was approved by the Mayo Clinic institutional review board and registered at [ClinicalTrials.gov](http://ClinicalTrials.gov) in January 2010 ([ClinicalTrials.gov](http://ClinicalTrials.gov) Identifer NCT01054469). Written, informed consent was obtained from 21 patients aged 23--79 years. Initially, we had planned to enroll 50 patients over 2 years, but recruitment proved slower than anticipated, compounded by a surgeon taking a leave of absence, which prevented that goal from being reached before institutional funding expired.

Patients were enrolled if they were aged 18--80 years and were scheduled to undergo hand-assisted laparoscopic removal of a single kidney for either tumor or living donor nephrectomy. Exclusion criteria included: planned bilateral nephrectomy, pregnancy or lactation, inability or refusal to provide informed consent, inability to comprehend the use of a visual analog scale (VAS), an expressed desire for preemptive antiemetics, a history of opioid tolerance, known prior allergy to amide local anesthetics or any of the study drugs (morphine), and a contraindication to regional nerve block (bleeding disorder, infection at site of block). Patients who were converted to open surgery due to intraoperative complications were considered a screen failure and were excluded from further participation in the study.

Participants were randomized in a double-blind fashion. The randomization chart was prepared by the statistician using the permuted block approach to achieve equal numbers of participants in each group. Participants received either 20 mL of 0.5% ropivacaine hydrochloride or 20 mL of 0.9% normal saline (placebo) bilaterally. The study medication or placebo was dispensed by the operating room pharmacy and was not disclosed to the anesthesiologist performing the block, administering the anesthesia during the case, or performing the evaluations postoperatively. Patients were given mild sedation consisting of midazolam and fentanyl at the discretion of the investigator prior to administration of the block, as per standard clinical care. They then underwent bilateral TAP block immediately before surgery in the preoperative holding bay. The technique for TAP block is well described and consists of identification of the lumbar "triangle of Petit" and subsequent injection of local anesthetic into the fascial plane between the internal oblique and transversus muscles using ultrasound guidance to ensure proper placement.[@b6-lra-7-011],[@b7-lra-7-011]

Participants received standard general anesthesia induction doses of propofol (2--3 mg/kg), fentanyl (up to 250 μg), and vecuronium or cisatracurium (titrated to maintain train-of-four at one twitch using a nerve stimulator). Anesthesia was maintained with isoflurane at 1 minimum alveolar concentration (MAC) with intermittent fentanyl boluses to a maximum of 250 μg. Fentanyl was not administered after initiation of skin closure. No pre-emptive antiemetics were administered. Postoperatively, participants were given intravenous patient-controlled morphine analgesia dosed at 1 mg with an 8-minute lockout. For inadequate pain control, defined as a pain score \>4, the dose was increased to 1.5 mg every 8 minutes. Rescue doses were administered at the discretion of the attending physician. Ideally, only morphine sulfate was to be used for breakthrough pain. If another opioid was administered, we converted the dose, using standard tables, to morphine equivalents. We assessed pain score (at rest and with movement) using a VA S at 0, 2, 6, 12, and 24 hours postoperatively. Pain scores were recorded as 0 (no pain) to 10 (worst pain ever). Additionally, we assessed the time to first request for analgesia and the total amount of morphine at each time interval. We also assessed the presence of postoperative nausea and vomiting, the need for rescue antiemetics, and the level of sedation recorded as 0 (awake and alert), 1 (appears asleep but awakes easily), 2 (asleep, difficult to arouse), or 3 (deep sleep). All patients complaining of nausea and requesting an antiemetic were treated with ondansetron 4 mg. This dose could be repeated if needed.

Surgical exposure was obtained using either a 7 cm supraumbilical or infraumbilical midline incision and 2--3 laparoscopic port entry sites as determined by the surgeon. Incisions for the port sites ranged from 5 mm to 12 mm and were on the ipsilateral side. Intra-abdominal insufflation with carbon dioxide was limited to 15 mmHg.

Statistical analysis
--------------------

Study data were collected and managed using REDCap (Research Electronic Data Capture) tools hosted at Mayo Clinic. REDCap is a secure, web-based application designed to support data capture for research studies. It provides an interface for data entry, audit trails, automated export to statistical programs, and procedures for importing data from an external source.[@b8-lra-7-011]

Numerical variables were primarily summarized with the sample median (minimum, 25th percentile, 75th percentile, maximum) while categorical variables were summarized with number and percentage. In the evaluation of all primary and secondary aims, comparison of treatment groups (placebo versus active) was performed using Fisher's exact test for categorical variables and the Wilcoxon rank-sum test for continuous variables, while time to first request of opiates was evaluated using the log-rank test. The data were analyzed using SAS version 9.2 (SAS Institute Inc., Cary, NC, USA). *P*-values ≤0.05 were considered to be statistically significant.

The study was designed to enroll 5 0 patients (25 per group), and was estimated to have 80% power to detect a 14 mg difference in opiate consumption. With the smaller than planned sample size, the possibility of a type II error should be considered when interpreting the results.

Results
=======

The characteristics for all 21 participants and for those in the placebo versus active treatment groups are summarized in [Table 1](#t1-lra-7-011){ref-type="table"}. Participants ranged in age from 2 3 to 7 9 (median 5 3) years of age and 12 (57%) were male. The median operative time was 217 minutes in the active treatment group and 168 minutes in the group that received placebo, while median length of stay was 2 days in both groups. There were no complications related to TAP block placement.

Comparison of postoperative opiate consumption between the two groups is summarized in [Table 2](#t2-lra-7-011){ref-type="table"}. Median 24-hour total opiate consumption was lower in the active treatment group than in the placebo group (26.6 mg versus 48.7 mg, *P*=0.13, respectively). The median amount of time after surgery until the first request for morphine by the participant was 59 minutes in the active treatment group and 50 minutes in the placebo group (*P*=0.37).

Post-surgical abdominal pain, as measured by the VAS, was compared between the two groups ([Table 3](#t3-lra-7-011){ref-type="table"}). There was no evidence of a difference in VAS pain scores between the two groups during the first 12 hours after surgery, either at rest (all *P*≥0.47) or with bending of the knee (all *P*≥0.62). However, at 24 hours after surgery, median VAS pain scores were significantly lower for the active treatment group compared with the placebo group, both at rest (1 versus 4, *P*=0.017) and with bending of the knee (1 versus 5, *P*=0.002). Although we did not formally evaluate the trend in pain scores over time, there is some evidence of a trend toward increased pain scores over the 24-hour post-surgery time period in the placebo group ([Table 3](#t3-lra-7-011){ref-type="table"}).

The incidence of nausea and vomiting after surgery is compared between the two groups in [Table 4](#t4-lra-7-011){ref-type="table"}. There was a trend toward a lower incidence of nausea in the 24 hours after surgery in the active treatment group compared with the placebo group (50% versus 91%, *P*=0.064). However, there was no evidence of a difference in incidence of vomiting during the 24 hours after surgery between the two groups (20% versus 20%, *P*=1.00). There were significantly fewer requests for an antiemetic after surgery in the active treatment group than in the placebo group (50% versus 100%, *P*=0.012).

The post-surgery sedation scores are compared for the two patient groups in [Table 5](#t5-lra-7-011){ref-type="table"}. The placebo group was more sedated than the active treatment group immediately after surgery, with eight (73%) patients in the placebo group versus only two patients (20%) in the active treatment group (*P*=0.009) being either asleep or in a deep sleep. There was no evidence of a difference in sedation level between the two groups at 2 and 24 hours after surgery (all *P*≥0.58).

Discussion
==========

As ultrasound-guided techniques have improved the efficacy and safety of TAP blocks, there has been a renewed interest in their use to provide analgesia to the anterior abdominal wall. Multiple studies support the theory that TAP blocks are effective in controlling pain for a variety of upper and lower abdominal surgeries.[@b6-lra-7-011],[@b7-lra-7-011],[@b9-lra-7-011],[@b10-lra-7-011] However, recent evidence suggests that these blocks may not be equally effective for all types of surgery.[@b5-lra-7-011],[@b11-lra-7-011]--[@b13-lra-7-011] This variation may be due to differences in the technique, timing, or amount of local anesthetic used.[@b10-lra-7-011] In this study, we investigated whether TAP blocks would be effective in providing analgesia to patients undergoing hand-assisted laparoscopic nephrectomy in the hope that we could improve patient satisfaction with regard to pain, Nausea, and somnolence.

In our small randomized study, there was a trend, albeit not statistically significant, towards a decrease in total opiate consumption in the 24 hours after nephrectomy among patients who received the TAP block compared with those who received a sham TAP block with saline (placebo). This observation is consistent with prior published studies, which have shown improved pain control in the first 24 hours postoperatively.[@b14-lra-7-011]--[@b16-lra-7-011] This improvement in overall pain is also reflected by the decrease in pain scores at 24 hours, at both rest and with movement. The resulting decrease in opioid consumption may also be the reason for the parallel decrease in incidence of Nausea in the active group when compared with the placebo group. The benefit gained in pain relief at 24 hours did not translate to improved time to discharge or overall sedation scores.

The use of TAP blocks in transplant anesthesia is growing. They have been described for kidney transplant recipients,[@b2-lra-7-011],[@b3-lra-7-011],[@b5-lra-7-011] liver transplant,[@b17-lra-7-011] and in control of immediate postoperative pain following pancreas transplant.[@b18-lra-7-011] To date, only one prospective study has described the use of TAP blocks in kidney donors.[@b4-lra-7-011] Hosgood et al administered 0.375% bupivacaine using a similar technique to that used in this study.[@b4-lra-7-011] We chose ropivacaine due to its safer cardiovascular risk profile in the event of accidental intravascular injection.[@b19-lra-7-011] As in our study, Hosgood et al found that pain scores were reduced at 24 and 48 hours. Additionally, total morphine consumption was significantly less in the first 6 hours (active, 12.4 mg; control, 2 1.2 mg; *P*=0.015) but the difference lost its statistical significance over 48 hours. Hosgood et al also showed no benefit with regard to time to discharge or rates of nausea/vomiting, but did show improved sedation scores in the control group.

Due to the finite duration of action associated with a single injection of local anesthetic, addition of a catheter for continuous infusion may improve pain control in these patients. Jankovic et al[@b3-lra-7-011] described intraoperative placement of a catheter by the surgeon into the space between the transversus muscle and the internal oblique. This resulted in improved pain control in seven patients when compared with a historical group. They found that prior attempts to place the catheter transcutaneously resulted in a high failure rate. Subcostal approaches to catheter placement have been described.[@b20-lra-7-011],[@b21-lra-7-011] More studies looking at this modality in relation to living kidney donors are needed to fully assess its viability.

This study is not without limitations. Its small sample size prevented formal analysis of trends in opiate consumption, abdominal pain, nausea, vomiting, and sedation over time. Although we did find some significant differences between the two groups, our study still lacked power, and therefore the possibility of a type II error (ie, a false negative association) should be considered. Additionally, in order to maintain a blinded study, skin sensation was not assessed prior to surgery. In clinical practice, adequacy of the block would have been assessed prior to skin incision. In an attempt to minimize this variance, ultrasound was used and a regional anesthesiologist with experience in TAP blocks performed the procedures.

In summary, we found that TAP blocks reduced overall pain scores at 24 hours, with a trend toward decreased total morphine consumption. Nausea, vomiting, sedation, and time to discharge were not significantly different between the two study groups. Further large-scale studies should be undertaken to fully evaluate the clinical utility of this technique in renal transplant patients as well as in patients undergoing resection for tumor.
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###### 

Patient characteristics

  Variable[a](#tfn1-lra-7-011){ref-type="table-fn"}                                            Overall (n=21)       Placebo (n=11)       Active (n=10)
  -------------------------------------------------------------------------------------------- -------------------- -------------------- --------------------
  Age at surgery, years                                                                        53 (23--79)          53 (40--79)          53 (23--74)
  Male                                                                                         12 (57%)             6 (60%)              6 (55%)
  Body mass index, kg/m^2^                                                                     24.3 (20.0--31.9)    25.0 (20.0--31.9)    23.9 (22.0--30.2)
  Side of surgery, left                                                                        16 (76%)             7 (70%)              9 (82%)
  Operative time (minutes)                                                                     181 (102--269)       168 (102--224)       217 (109--269)
  Minutes from needle insertion to block completion[b](#tfn2-lra-7-011){ref-type="table-fn"}   15 (4--33)           13 (4--33)           15 (10--20)
  Blood reflux from needle[c](#tfn3-lra-7-011){ref-type="table-fn"}                            0 (0%)               0 (0%)               0 (0%)
  Time from end of surgery to Foley catheter removal (hours)                                   19.9 (17.6--382.9)   20.0 (17.6--330.9)   19.9 (18.8--382.9)
  Days from surgery to discharge                                                               2 (2--6)             2 (2--4)             2 (2--6)

**Notes:**

Categorical variables are reported as n (%), continuous variables are reported with median (minimum, maximum)

four patients in the placebo group and two in the active group did not have needle insertion time collected

two placebo patients did not have blood reflux from needle data collected.

###### 

Postoperative morphine consumption

  Variable[a](#tfn4-lra-7-011){ref-type="table-fn"}           Placebo (n=11)                  Active (n=10)                    *P*-value[b](#tfn5-lra-7-011){ref-type="table-fn"}
  ----------------------------------------------------------- ------------------------------- -------------------------------- ----------------------------------------------------
  Total pain medication at hour 0 (mg)                        0.0 (0.0, 0.0, 1.7, 6.7)        0.0 (0.0, 0.0, 0.0, 0.0)         0.094
  Total pain medication at hour 2 (mg)                        6.7 (0.0, 2.6, 10.0, 12.0)      2.0 (0.0, 0.0, 7.2, 20.0)        0.38
  Total pain medication at hour 6 (mg)                        10.7 (0.0, 3.3, 14.6, 28.6)     6.6 (0, 2.2, 9.9, 34.8)          0.50
  Total pain medication at hour 12 (mg)                       8.0 (0.0, 5.3, 14.7, 28.0)      8.8 (0.0, 4.1, 10.0, 20.0)       0.83
  Total pain medication at hour 24 (mg)                       12.7 (0.0, 6.6, 37.0, 55.5)     9.0 (0.0, 3.3, 10.0, 97.3)       0.20
  Total 24-hour opiate consumption (mg)                       48.7 (14.0, 24.4, 73.3, 84.6)   26.6 (11.7, 16.5, 36.3, 151.3)   0.13
  Minutes from end of surgery to first PCA morphine request   50 (16, 36, 90, 166)            59 (30, 48, 115, 455)            0.37[c](#tfn6-lra-7-011){ref-type="table-fn"}

**Notes:**

Continuous variables are reported with median (minimum, 25th percentile, 75th percentile, maximum)

*P*-value given based on Wilcoxon rank sum test

*P*-value given based on log rank test.

**Abbreviation:** PCA, patient-controlled morphine analgesia.

###### 

Abdominal pain score post surgery at rest and with bending knee

  --------------------------------------------------------------------------------------------------------------------------------------------
  Variable[a](#tfn8-lra-7-011){ref-type="table-fn"}   Placebo\                                                   Active\           *P*-value
                                                      (n=11)                                                     (n=10)            
  --------------------------------------------------- ---------------------------------------------------------- ----------------- -----------
  VAS pain score at rest hour 0                       1 (0, 0, 6, 10)[b](#tfn9-lra-7-011){ref-type="table-fn"}   0 (0, 0, 6, 10)   0.85

  VAS pain score at rest hour 2                       2 (0, 0, 5, 10)                                            1 (0, 0, 3, 6)    0.61

  VAS pain score at rest hour 6                       2 (0, 1, 5, 10)                                            3 (0, 2, 4, 6)    0.89

  VAS pain score at rest hour 12                      3 (1, 1, 4, 10)                                            2 (0, 1, 5, 5)    0.47

  VAS pain score at rest hour 24                      4 (0, 2, 6, 8)                                             1 (0, 0, 2, 4)    0.017

  VAS pain score with bending knee hour 0             1 (0, 0, 6, 10)[b](#tfn9-lra-7-011){ref-type="table-fn"}   0 (0, 0, 6, 10)   0.85

  VAS pain score with bending knee hour 2             2 (0, 0, 6, 10)[b](#tfn9-lra-7-011){ref-type="table-fn"}   1 (0, 0, 4, 6)    0.68

  VAS pain score with bending knee hour 6             2 (0, 0, 5, 10)                                            3 (0, 0, 4, 7)    0.97

  VAS pain score with bending knee hour 12            4 (0, 1, 6, 10)                                            3 (0, 0, 5, 7)    0.62

  VAS pain score with bending knee hour 24            5 (2, 3, 7, 10)                                            1 (0, 0, 2, 6)    0.002
  --------------------------------------------------------------------------------------------------------------------------------------------

**Notes:**

Continuous variables are reported with median (minimum, 25th percentile, 75th percentile, maximum)

information was not collected for one patient

*P*-value given based on Wilcoxon rank sum test.

**Abbreviation:** VAS, visual analog scale.

###### 

Nausea and vomiting post surgery

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variable[a](#tfn12-lra-7-011){ref-type="table-fn"}   Placebo\                                            Active\   *P*-value[c](#tfn14-lra-7-011){ref-type="table-fn"}
                                                       (n=11)                                              (n=10)    
  ---------------------------------------------------- --------------------------------------------------- --------- -----------------------------------------------------
  Nausea hour 0                                        2 (20%)[b](#tfn13-lra-7-011){ref-type="table-fn"}   2 (20%)   1.00

  Nausea hour 2                                        3 (27%)                                             2 (20%)   1.00

  Nausea hour 6                                        5 (45%)                                             4 (40%)   1.00

  Nausea hour 12                                       3 (27%)                                             2 (20%)   1.00

  Nausea hour 24                                       3 (30%)[b](#tfn13-lra-7-011){ref-type="table-fn"}   1 (10%)   0.58

  Any nausea within 24 hours after surgery             10 (91%)                                            5 (50%)   0.064

  Vomiting hour 0                                      0 (0%)[b](#tfn13-lra-7-011){ref-type="table-fn"}    0 (0%)    NA

  Vomiting hour 2                                      0 (0%)[b](#tfn13-lra-7-011){ref-type="table-fn"}    0 (0%)    NA

  Vomiting hour 6                                      1 (10%)[b](#tfn13-lra-7-011){ref-type="table-fn"}   1 (10%)   1.00

  Vomiting hour 12                                     1 (10%)[b](#tfn13-lra-7-011){ref-type="table-fn"}   1 (10%)   1.00

  Vomiting hour 24                                     0 (0%)[b](#tfn13-lra-7-011){ref-type="table-fn"}    0 (0%)    NA

  Any vomiting within 24 hours after surgery           2 (20%)[b](#tfn13-lra-7-011){ref-type="table-fn"}   2 (20%)   1.00

  Requested antiemetic after surgery                   11 (100%)                                           5 (50%)   0.012
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:**

Categorical variables are reported as n (%), continuous variables are reported with median (minimum, 25th percentile, 75th percentile, maximum)

information was not collected for one patient

*P*-value given based on Fisher's exact test unless otherwise specified.

###### 

Sedation post surgery

  -------------------------------------------------------------------------------------------------------------------------------
  Variable[a](#tfn15-lra-7-011){ref-type="table-fn"}   Placebo\   Active\   *P*-value[b](#tfn16-lra-7-011){ref-type="table-fn"}
                                                       (n=11)     (n=10)    
  ---------------------------------------------------- ---------- --------- -----------------------------------------------------
  Sedation hour 0                                                           0.009

   Awake and alert                                     0 (0%)     1 (10%)   

   Awakens easily                                      3 (27%)    7 (70%)   

   Asleep                                              8 (73%)    1 (10%)   

   Deep sleep                                          0 (0%)     1 (10%)   

  Sedation hour 2                                                           0.67

   Awake and alert                                     0 (0%)     1 (10%)   

   Awakens easily                                      9 (82%)    7 (70%)   

   Asleep                                              2 (18%)    1 (10%)   

   Deep sleep                                          0 (0%)     1 (10%)   

  Sedation hour 6                                                           1.00

   Awake and alert                                     4 (36%)    4 (40%)   

   Awakens easily                                      7 (64%)    6 (60%)   

   Asleep                                              0 (0%)     0 (0%)    

   Deep sleep                                          0 (0%)     0 (0%)    

  Sedation hour 12                                                          0.67

   Awake and alert                                     5 (45%)    6 (60%)   

   Awakens easily                                      6 (55%)    4 (40%)   

   Asleep                                              0 (0%)     0 (0%)    

   Deep sleep                                          0 (0%)     0 (0%)    

  Sedation hour 24                                                          0.58

   Awake and alert                                     10 (91%)   8 (80%)   

   Awakens easily                                      1 (9%)     2 (20%)   

   Asleep                                              0 (0%)     0 (0%)    

   Deep sleep                                          0 (0%)     0 (0%)    
  -------------------------------------------------------------------------------------------------------------------------------

**Notes:**

Categorical variables are reported as n (%)

*P*-value given based on Fisher's exact test.
